stethoscope

Join our network and find credentialing information.

Log in to Availity Essentials™ to access patient benefits, claims information and more.

Find tools and materials to support doing business with us.

Learn more about research and trends that impact your practice.

Find self-service info and phone numbers and update your provider data.

Review prior authorization lists for services, medications and submission guidance.

Prior authorization submission information

Professionally administered drugs prior authorization

Find appeals guidelines and payment policy information.

Learn how to submit claims and find coding guidance.

Find policies for procedures, devices and medications.

Review guidelines and health programs to support your patients and practice.

Find dental benefits, tools and resources.

Prior authorization for professionally administered drugs 

Locate state-specific resources for Humana Healthy Horizons® (Medicaid).

compass

Shop plans, learn about Medicare and explore member resources.

Search for in-network medical, vision, dental and pharmacy providers.

Drug recall notice for quinapril products

A couple researching a prescription online

To assist you in the care of your patients, we would like to alert you to the recall of some quinapril products, effective October 2022.1,2 We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them of the recall. We have listed alternative options below.

The U.S. Food and Drug Administration (FDA) announced that recent testing showed results of a nitrosamine drug substance-related impurity, N-nitroso-quinapril, above the acceptable daily intake level.1,2 The N-nitroso-quinapril impurity has been classified as a probable human carcinogen by the International Agency for Research on Cancer. The FDA contacted several companies recommending they voluntarily recall their products. Assessments are underway to determine whether quinapril product recalls will result in shortages, and the FDA will work closely with manufacturers to prevent or reduce any impact of shortages.    

To date, the manufacturers have received no reports of adverse events related to this recall.

Information for providers:1,2

    We have sent a letter to your Humana-covered patients who have had a claim for quinapril products and asked them to contact their physicians or healthcare providers if their medication is included in the recall and if they have experienced problems that may be related to using these drug products. 

    Patients may report adverse reactions or quality problems experienced with the use of these products to the FDA’s MedWatch Adverse Event Reporting Program online, by regular mail or by fax.            Online: Complete and submit the report.                    Select “Consumer/Patient (FDA Form 3500B).” 



        Regular mail or fax: Download the form                    Select “Form FDA 3500B – Voluntary Reporting for Consumers” and submit by mail to the address on the form or by fax to 800-FDA-0178 (332-0178).







    “Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, Due to the Detection of N-Nitroso Quinapril Impurity,” U.S. Food and Drug Administration, last accessed Jan. 3, 2023, www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-recall-two-2-lots-quinapril-and.

    “Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets Due to Potential Presence of N-Nitroso-Quinapril Impurity,” U.S. Food and Drug Administration, last accessed Jan. 3, 2023, www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/lupin-pharmaceuticals-inc-issues-voluntary-nationwide-recall-four-lots-quinapril-tablets-due.



Drug recall notice for Nature-Throid and WP Thyroid tablets

Drug recall notice for Belviq, Belviq XR (lorcaserin)

Drug recall notice for NP Thyroid tablets

Drug recall notice for Taro Pharmaceuticals phenytoin oral suspension

Formulary changes for generic Ventolin HFA

Impact of ongoing angiotensin II receptor blocker drug recalls

Product name	NDC number	Lot number	Expiration date
Quinapril and hydrochlorothiazide 20 mg/12.5 mg tablets, 90-count bottle¹	65862-0162-90	QE2021005-A, QE2021010-A	01/2023 01/2023
Quinapril 20 mg tablets²	68180-0558-09	G102929	04/2023
Quinapril 40 mg tablets²	68180-0554-09	G100533 G100534 G203071	12/2022 12/2022 03/2024

Medication	Preferred alternatives
Quinapril and hydrochlorothiazide	Lisinopril and hydrochlorothiazide
Quinapril	Lisinopril

Medications included in this recall

Recommendations

References:

Pharmacy news